Table 3.

ERG responses and retinal findings in study 2 after subretinal injection of AAV5-PR2.1-hCNGB3 in CNGB3-mutant dogs

Group	Animal ID	Eye	Vector dose (vg/eye)	Cone ERG (μV)	Clinical ophthalmic examination	Histopathologic findings in retina
1	GS225	OD	7.5 × 109	0	Focal retina thinning	Focal inner and outer nuclear layer attenuation
		OS	7.5 × 109	0	Normala	Focal disruption of retinal architecture; minimal neuroretinal accumulation of mononuclear inflammatory cells
2	GS226	OD	7.5 × 1010	2.12	Retinal fold; focal retinal thinning	Focal detachment with associated focal neuroretinal (predominantly perivascular) accumulation of mononuclear inflammatory cells; rare vitreal inflammatory cells
		OS	7.5 × 1010	2.90	Retinal fold; focal retinal thinning	Moderate neuroretinal (predominantly perivascular) accumulation of mononuclear inflammatory cells; rare vitreal inflammatory cells
	GS229	OD	7.5 × 1010	13.00	Normala	Multifocal, predominantly perivascular mononuclear inflammation of the neuroretina
		OS	7.5 × 1010	19.10	Discoloration at injection site	Focal neuroretinal atrophy (retinotomy scar)
3	GS228	OD	7.5 × 1011	0	Multifocal chorioretinitis started at week 7	No significant lesions
		OS	7.5 × 1011	0	Multifocal chorioretinitis started at week 4	Locally extensive retinal attenuation with neuroretinal parenchymal and perivascular accumulation of mononuclear inflammatory cells; rare vitreal inflammatory cells
	GS233	OD	7.5 × 1011	3.41	Multifocal chorioretinitis started at week 6	Focal retinal detachment with neuroretinal parenchymal and perivascular mononuclear inflammation; retinal pigment epithelium loss and associated inflammation
		OS	7.5 × 1011	2.73	Multifocal chorioretinitis started at week 6	Locally extensive marked retinal atrophy; perivascular mononuclear inflammation

Each animal received a 0.15 mL subretinal injection of AAV5-PR2.1-hCNGB3 in both eyes (OD and OS).

^aNormal except for retinotomy scar which was seen in all eyes.

ERG, electroretinogram.